In two out of five cases (colon adenocarcinoma and skin cutaneous melanoma), p53 deficiency was associated with increased drug sensitivity, whereas in the other three comparisons (breast invasive carcinoma, ovarian serous cystadenocarcinoma, and pancreatic adenocarcinoma), p53 deficiency was associated with decreased drug sensitivity (Fig. 2B). This evidence concerns the gene TP53 and ovarian serous cystadenocarcinoma.